Pam Marcus, Ph.D.
Program Director, Clinical and Translational Epidemiology Branch
- Telephone: (240) 276-6901
- Fax: (240) 276-7920
- E-mail: firstname.lastname@example.org
Epidemiology and Genomics Research Program
Division of Cancer Control and Population Sciences
National Cancer Institute
National Institutes of Health
9609 Medical Center Drive, Rm. 4E608, MSC 9763
Bethesda, MD 20892
(For express delivery, use Rockville, MD 20850)
- Cancer epidemiology and screening
- Cancer risk in persons with chronic conditions
- Operations and management of large, multicenter initiatives, including clinical trials
- Lung cancer
- Ph.D. - Epidemiology
University of North Carolina, Chapel Hill
- M.S. - Preventive Medicine
University of Wisconsin–Madison
- M.S. - Statistics
University of Wisconsin–Madison
Dr. Pamela Marcus is an Epidemiologist in the Epidemiology and Genomics Research Program's (EGRP) Clinical and Translational Epidemiology Branch (CTEB). She is leading efforts in the area of cancer screening that aim to improve cancer screening through a number of avenues, including risk-stratified screening. Dr. Marcus also is assisting CTEB in its efforts to evaluate cancer risk in individuals who have chronic conditions or diseases. She is known for her expertise in cancer screening, particularly in the area of data interpretation. Dr. Marcus has a strong interest in developing materials that clearly explain complex topics in cancer screening, with the goal of improving their understanding by both lay persons and health professionals.
Dr. Marcus began her career at the NCI as a postdoctoral Cancer Prevention Fellow. From 1997 to 2011, she was a member of the Division of Cancer Prevention's Biometry Research Group. She worked on NCI's National Lung Screening Trial and the Prostate, Lung, Colorectal and Ovarian Cancer Screening Trial, two large randomized controlled trials examining the efficacy of various screening modalities. During that time, she published extensively on lung cancer screening. Dr. Marcus moved to the Applied Research Program (ARP) in NCI's Division of Cancer Control and Population Sciences (DCCPS) in 2011 to lead the Population-Based Research Optimizing Screening through Personalized Regimens (PROSPR) Initiative, an observational study of the breast, cervical, and colorectal cancer screening processes in clinical settings. Dr. Marcus also worked with the Breast Cancer Surveillance Consortium (BCSC) investigators to facilitate establishment of the BCSC Research Resource, a data and analysis resource available for free to the research community and the general public. She joined EGRP in August 2013.
Marcus PM, Kramer BS. Screening for prostate cancer with prostate-specific antigen (PSA): What's the evidence? In: Govindan R, ed. 2012 ASCO Educational Book. Alexandria, VA: American Society of Clinical Oncology; 2012.
The National Lung Screening Research Team. Reduced lung cancer mortality with low-dose computed tomographic screening. N Engl J Med. 2011;365:395-409.
Marcus PM, Gareen IF, Miller AB, Rosenbaum J, Keating K, Aberle DR, Berg CD. The National Lung Screening Trial's endpoint verification process: determining the cause of death. Contemp Clin Trials. 2011;32(6):834-40.
Marcus PM, Bergstralh EJ, Zweig MH, Harris A, Offord KP, Fontana RS. Extended lung cancer incidence follow-up in the Mayo Lung Project: additional support for overdiagnosis. J Natl Cancer Inst. 2006; 98:748-756.
Marcus PM, Bergstralh EJ, Fagerstrom RM, Fontana RS, Taylor W, Prorok PC. Lung cancer mortality in the Mayo Lung Project: the impact of extended follow-up. J Natl Cancer Inst. 2000;92:1308-1316.
Marcus PM. Television as a venue for cancer education: the General Hospital experience. J Cancer Educ. 2000;15:4.
Marcus PM, Newman B, Millikan RC, Moorman PG, Baird DD, Qaqish B. The association of adolescent cigarette smoking, alcoholic beverage consumption, environmental tobacco smoke, and ionizing radiation with subsequent breast cancer risk. Cancer Causes and Control. 2000; 11:271-278.